TY - JOUR
T1 - Familial autosomal recessive renal tubular acidosis
T2 - Importance of early diagnosis
AU - Vivante, Asaf
AU - Lotan, Danny
AU - Pode-Shakked, Naomi
AU - Landau, Daniel
AU - Svec, Peter
AU - Nampoothiri, Sheela
AU - Verma, Ishwar
AU - Abu-Libdeh, Abdulsalam
AU - Bockenhauer, Detlef
AU - Dekel, Benjamin
AU - Anikster, Yair
PY - 2011/10
Y1 - 2011/10
N2 - Background and Aims: Untreated renal tubular acidosis (RTA) can result in severe complications. We reviewed the clinical features of patients with mutations in two genes causing RTA and evaluated their developmental expression assuming that timing, symptom severity and complications may be related to its occurrence. Methods: Clinical data from 16 patients with RTA due to mutations in either ATP6V1B1 or CAII were retrospectively reviewed. Both genes' localization and expression pattern in the developing human kidney were analyzed by real-time polymerase chain reaction and immunostaining. Results: RTA-presenting symptoms were non-specific. Patients with mutations in ATP6V1B1 had earlier presentation (4.9 vs. 11 months, p < 0.041) and longer time to diagnosis than patients with CAII mutations (5.8 vs. 57 months, p < 0.01). Patients with ATP6V1B1 mutations were more likely to develop chronic kidney disease than those with CAII mutations (follow-up GFR values: 89 vs. 110 ml/min/1.73 m 2, respectively, p < 0.017), probably secondary to nephrocalcinosis. Both ATP6V1B1 and CAII were expressed early during human nephrogenesis, with relatively higher transcript levels of ATP6V1B1. Conclusions: There is considerable delay in establishing a diagnosis of both types of RTA, supporting the need for earlier biochemical investigation. RTA due to ATP6V1B1 mutations is associated with mild progressive loss of kidney function.
AB - Background and Aims: Untreated renal tubular acidosis (RTA) can result in severe complications. We reviewed the clinical features of patients with mutations in two genes causing RTA and evaluated their developmental expression assuming that timing, symptom severity and complications may be related to its occurrence. Methods: Clinical data from 16 patients with RTA due to mutations in either ATP6V1B1 or CAII were retrospectively reviewed. Both genes' localization and expression pattern in the developing human kidney were analyzed by real-time polymerase chain reaction and immunostaining. Results: RTA-presenting symptoms were non-specific. Patients with mutations in ATP6V1B1 had earlier presentation (4.9 vs. 11 months, p < 0.041) and longer time to diagnosis than patients with CAII mutations (5.8 vs. 57 months, p < 0.01). Patients with ATP6V1B1 mutations were more likely to develop chronic kidney disease than those with CAII mutations (follow-up GFR values: 89 vs. 110 ml/min/1.73 m 2, respectively, p < 0.017), probably secondary to nephrocalcinosis. Both ATP6V1B1 and CAII were expressed early during human nephrogenesis, with relatively higher transcript levels of ATP6V1B1. Conclusions: There is considerable delay in establishing a diagnosis of both types of RTA, supporting the need for earlier biochemical investigation. RTA due to ATP6V1B1 mutations is associated with mild progressive loss of kidney function.
KW - ATP6V1B1
KW - CAII
KW - Kidney development
KW - Renal tubular acidosis
UR - http://www.scopus.com/inward/record.url?scp=80051644515&partnerID=8YFLogxK
U2 - 10.1159/000329668
DO - 10.1159/000329668
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:80051644515
VL - 119
SP - p31-p39
JO - Nephron - Clinical Practice
JF - Nephron - Clinical Practice
SN - 1660-2110
IS - 3
ER -